FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
- FLASCO
- June 30, 2022
- Uncategorized
What safety concern is FDA announcing?
The U.S. Food and Drug Administration (FDA) is warning that results from a clinical trial show a possible increased risk of death with Copiktra (duvelisib) compared to another medicine to treat a chronic blood cancer called leukemia and a lymphoma, a cancer found in the lymph nodes. The trial also found Copiktra was associated with a higher risk of serious side effects, including infections, diarrhea, inflammation of the intestines and lungs, skin reactions, and high liver enzyme levels in the blood.
